Compile Data Set for Download or QSAR
Report error Found 63 Enz. Inhib. hit(s) with all data for entry = 10910
TargetLarge envelope protein(HBV-D)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577456(US11472826, # 18)
Affinity DataEC50:  5.50E+3nMAssay Description:Determination of 50% inhibitory concentration (EC50) of compounds in HCV replicon cells were performed by the following procedure. On the first day, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577390(US11472826, # 1 | (2-((4-aminopyrrolo[2,1-f][1,2,4...)
Affinity DataEC50: <1.00E+3nMAssay Description:Determination of 50% inhibitory concentration (EC50) of compounds in HCV replicon cells were performed by the following procedure. On the first day, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577416(US11472826, # 2 | (R)-(((1-(4-aminopyrrolo[2,1-f][...)
Affinity DataEC50:  5.50E+4nMAssay Description:Determination of 50% inhibitory concentration (EC50) of compounds in HCV replicon cells were performed by the following procedure. On the first day, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577422(US11472826, # 8 | (((1-(4-amino-2-fluoropyrrolo[2,...)
Affinity DataEC50:  5.50E+4nMAssay Description:Determination of 50% inhibitory concentration (EC50) of compounds in HCV replicon cells were performed by the following procedure. On the first day, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577423(US11472826, # 9 | (((1-(2,4-diaminopyrrolo[2,1-f][...)
Affinity DataEC50:  5.50E+3nMAssay Description:Determination of 50% inhibitory concentration (EC50) of compounds in HCV replicon cells were performed by the following procedure. On the first day, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577424(US11472826, # 10 | US11472826, # 10c | US11472826,...)
Affinity DataEC50:  5.50E+3nMAssay Description:Determination of 50% inhibitory concentration (EC50) of compounds in HCV replicon cells were performed by the following procedure. On the first day, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577424(US11472826, # 10 | US11472826, # 10c | US11472826,...)
Affinity DataEC50:  5.50E+3nMAssay Description:Determination of 50% inhibitory concentration (EC50) of compounds in HCV replicon cells were performed by the following procedure. On the first day, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577424(US11472826, # 10 | US11472826, # 10c | US11472826,...)
Affinity DataEC50:  5.50E+3nMAssay Description:Determination of 50% inhibitory concentration (EC50) of compounds in HCV replicon cells were performed by the following procedure. On the first day, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577425(US11472826, # 11 | (1-(4-aminopyrazolo[1,5-a][1,3,...)
Affinity DataEC50: <1.00E+3nMAssay Description:Determination of 50% inhibitory concentration (EC50) of compounds in HCV replicon cells were performed by the following procedure. On the first day, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577426(US11472826, # 12)
Affinity DataEC50: <1.00E+3nMAssay Description:Determination of 50% inhibitory concentration (EC50) of compounds in HCV replicon cells were performed by the following procedure. On the first day, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577427(US11472826, # 13 | (((1-(4-oxo-3,4-dihydropyrrolo[...)
Affinity DataEC50: >1.00E+5nMAssay Description:Determination of 50% inhibitory concentration (EC50) of compounds in HCV replicon cells were performed by the following procedure. On the first day, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577428(US11472826, # 14 | (((1-(2-amino-4-oxo-3,4-dihydro...)
Affinity DataEC50: <1.00E+3nMAssay Description:Determination of 50% inhibitory concentration (EC50) of compounds in HCV replicon cells were performed by the following procedure. On the first day, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577454(US11472826, # 15 | (S)-(((1-(4-aminopyrrolo[2,1-f]...)
Affinity DataEC50:  5.50E+3nMAssay Description:Determination of 50% inhibitory concentration (EC50) of compounds in HCV replicon cells were performed by the following procedure. On the first day, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577455(US11472826, # 16 | (((1-(2-amino-4-oxo-3,4-dihydro...)
Affinity DataEC50: <1.00E+3nMAssay Description:Determination of 50% inhibitory concentration (EC50) of compounds in HCV replicon cells were performed by the following procedure. On the first day, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577416(US11472826, # 2 | (R)-(((1-(4-aminopyrrolo[2,1-f][...)
Affinity DataEC50:  6.00E+4nMAssay Description:24 hours prior to infection, CEM human T lymphoblast cells (ATCC, Manassas, Va.) were plated in assay media (MEM supplemented with 10% FBS, 1% penici...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577457(US11472826, # 48 | (((1-(2-amino-4-oxo-3,4-dihydro...)
Affinity DataEC50: <1.00E+3nMAssay Description:Determination of 50% inhibitory concentration (EC50) of compounds in HCV replicon cells were performed by the following procedure. On the first day, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577458(US11472826, # 51)
Affinity DataEC50: <1.00E+3nMAssay Description:Determination of 50% inhibitory concentration (EC50) of compounds in HCV replicon cells were performed by the following procedure. On the first day, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577459(US11472826, # 52)
Affinity DataEC50: <1.00E+3nMAssay Description:Determination of 50% inhibitory concentration (EC50) of compounds in HCV replicon cells were performed by the following procedure. On the first day, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577460(US11472826, # 53)
Affinity DataEC50: <1.00E+3nMAssay Description:Determination of 50% inhibitory concentration (EC50) of compounds in HCV replicon cells were performed by the following procedure. On the first day, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577461(US11472826, # 61)
Affinity DataEC50: <1.00E+3nMAssay Description:Determination of 50% inhibitory concentration (EC50) of compounds in HCV replicon cells were performed by the following procedure. On the first day, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577462(US11472826, # 62)
Affinity DataEC50: <1.00E+3nMAssay Description:Determination of 50% inhibitory concentration (EC50) of compounds in HCV replicon cells were performed by the following procedure. On the first day, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577463(US11472826, # 63)
Affinity DataEC50: <1.00E+3nMAssay Description:Determination of 50% inhibitory concentration (EC50) of compounds in HCV replicon cells were performed by the following procedure. On the first day, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577464(US11472826, # 64 | ((1-((4-aminopyrazolo[1,5-a][1,...)
Affinity DataEC50:  5.50E+4nMAssay Description:Determination of 50% inhibitory concentration (EC50) of compounds in HCV replicon cells were performed by the following procedure. On the first day, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577465(US11472826, # 65 | (S) (((3-(4-aminoprazolo[1,5-a]...)
Affinity DataEC50:  5.50E+3nMAssay Description:Determination of 50% inhibitory concentration (EC50) of compounds in HCV replicon cells were performed by the following procedure. On the first day, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577466(US11472826, # 66 | (R)-(((3-(4-aminopyrazolo[1,5-a...)
Affinity DataEC50:  5.50E+3nMAssay Description:Determination of 50% inhibitory concentration (EC50) of compounds in HCV replicon cells were performed by the following procedure. On the first day, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577467(US11472826, # 67 | (S)-(((1-(4-aminoimidazo[2,1-f]...)
Affinity DataEC50:  5.50E+4nMAssay Description:Determination of 50% inhibitory concentration (EC50) of compounds in HCV replicon cells were performed by the following procedure. On the first day, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetLarge envelope protein(HBV-D)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577468(US11472826, # 68 | (R)-(((1-(4-aminoimidazo[2,1-f]...)
Affinity DataEC50: <1.00E+3nMAssay Description:Determination of 50% inhibitory concentration (EC50) of compounds in HCV replicon cells were performed by the following procedure. On the first day, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577390(US11472826, # 1 | (2-((4-aminopyrrolo[2,1-f][1,2,4...)
Affinity DataEC50: >1.00E+5nMAssay Description:24 hours prior to infection, CEM human T lymphoblast cells (ATCC, Manassas, Va.) were plated in assay media (MEM supplemented with 10% FBS, 1% penici...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577430(US11472826, # 30)
Affinity DataEC50: <2.00E+4nMAssay Description:24 hours prior to infection, CEM human T lymphoblast cells (ATCC, Manassas, Va.) were plated in assay media (MEM supplemented with 10% FBS, 1% penici...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577429(US11472826, # 29)
Affinity DataEC50:  6.00E+4nMAssay Description:24 hours prior to infection, CEM human T lymphoblast cells (ATCC, Manassas, Va.) were plated in assay media (MEM supplemented with 10% FBS, 1% penici...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577428(US11472826, # 14 | (((1-(2-amino-4-oxo-3,4-dihydro...)
Affinity DataEC50: <2.00E+4nMAssay Description:24 hours prior to infection, CEM human T lymphoblast cells (ATCC, Manassas, Va.) were plated in assay media (MEM supplemented with 10% FBS, 1% penici...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577427(US11472826, # 13 | (((1-(4-oxo-3,4-dihydropyrrolo[...)
Affinity DataEC50: <2.00E+4nMAssay Description:24 hours prior to infection, CEM human T lymphoblast cells (ATCC, Manassas, Va.) were plated in assay media (MEM supplemented with 10% FBS, 1% penici...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577426(US11472826, # 12)
Affinity DataEC50: <2.00E+4nMAssay Description:24 hours prior to infection, CEM human T lymphoblast cells (ATCC, Manassas, Va.) were plated in assay media (MEM supplemented with 10% FBS, 1% penici...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577425(US11472826, # 11 | (1-(4-aminopyrazolo[1,5-a][1,3,...)
Affinity DataEC50: <2.00E+4nMAssay Description:24 hours prior to infection, CEM human T lymphoblast cells (ATCC, Manassas, Va.) were plated in assay media (MEM supplemented with 10% FBS, 1% penici...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577424(US11472826, # 10 | US11472826, # 10c | US11472826,...)
Affinity DataEC50: <2.00E+4nMAssay Description:24 hours prior to infection, CEM human T lymphoblast cells (ATCC, Manassas, Va.) were plated in assay media (MEM supplemented with 10% FBS, 1% penici...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577423(US11472826, # 9 | (((1-(2,4-diaminopyrrolo[2,1-f][...)
Affinity DataEC50: <2.00E+4nMAssay Description:24 hours prior to infection, CEM human T lymphoblast cells (ATCC, Manassas, Va.) were plated in assay media (MEM supplemented with 10% FBS, 1% penici...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577422(US11472826, # 8 | (((1-(4-amino-2-fluoropyrrolo[2,...)
Affinity DataEC50:  6.00E+4nMAssay Description:24 hours prior to infection, CEM human T lymphoblast cells (ATCC, Manassas, Va.) were plated in assay media (MEM supplemented with 10% FBS, 1% penici...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577421(US11472826, # 7 | (1-(4-aminopyrazolo[1,5-a][1,3,5...)
Affinity DataEC50: <2.00E+4nMAssay Description:24 hours prior to infection, CEM human T lymphoblast cells (ATCC, Manassas, Va.) were plated in assay media (MEM supplemented with 10% FBS, 1% penici...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577420(US11472826, # 6 | (R)-(((1-(4-aminoimidazo[5,1-f][...)
Affinity DataEC50: >1.00E+5nMAssay Description:24 hours prior to infection, CEM human T lymphoblast cells (ATCC, Manassas, Va.) were plated in assay media (MEM supplemented with 10% FBS, 1% penici...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577419(US11472826, # 5 | (R)-(((1-(4-aminoimidazo[2,1-f][...)
Affinity DataEC50: <2.00E+4nMAssay Description:24 hours prior to infection, CEM human T lymphoblast cells (ATCC, Manassas, Va.) were plated in assay media (MEM supplemented with 10% FBS, 1% penici...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577418(US11472826, # 4 | (R)-(((1-(8-amino-[1,2,4]triazol...)
Affinity DataEC50: >1.00E+5nMAssay Description:24 hours prior to infection, CEM human T lymphoblast cells (ATCC, Manassas, Va.) were plated in assay media (MEM supplemented with 10% FBS, 1% penici...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577417(US11472826, # 3 | ((2-(4-aminopyrrolo[2,1-f][1,2,4...)
Affinity DataEC50: >1.00E+5nMAssay Description:24 hours prior to infection, CEM human T lymphoblast cells (ATCC, Manassas, Va.) were plated in assay media (MEM supplemented with 10% FBS, 1% penici...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetGag-Pol polyprotein(HIV-1)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577433(US11472826, # 21)
Affinity DataIC50: 50nMAssay Description:Recombinant full length HIV-1 Reverse Transcriptase (HIVrt) was purchased from Abcam, catalog #ab63979. The last 385 nucleotide region of the HCV ant...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetGag-Pol polyprotein(HIV-1)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577432(US11472826, # 20)
Affinity DataIC50: 50nMAssay Description:Recombinant full length HIV-1 Reverse Transcriptase (HIVrt) was purchased from Abcam, catalog #ab63979. The last 385 nucleotide region of the HCV ant...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetGag-Pol polyprotein(HIV-1)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577442(US11472826, # 56)
Affinity DataIC50: 50nMAssay Description:Recombinant full length HIV-1 Reverse Transcriptase (HIVrt) was purchased from Abcam, catalog #ab63979. The last 385 nucleotide region of the HCV ant...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetGag-Pol polyprotein(HIV-1)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577435(US11472826, # 23 | (((1-(2-amino-4-oxo-3,4-dihydro...)
Affinity DataIC50: 50nMAssay Description:Recombinant full length HIV-1 Reverse Transcriptase (HIVrt) was purchased from Abcam, catalog #ab63979. The last 385 nucleotide region of the HCV ant...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetGag-Pol polyprotein(HIV-1)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577444(US11472826, # 58)
Affinity DataIC50: 50nMAssay Description:Recombinant full length HIV-1 Reverse Transcriptase (HIVrt) was purchased from Abcam, catalog #ab63979. The last 385 nucleotide region of the HCV ant...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetGag-Pol polyprotein(HIV-1)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577445(US11472826, # 59)
Affinity DataIC50: 50nMAssay Description:Recombinant full length HIV-1 Reverse Transcriptase (HIVrt) was purchased from Abcam, catalog #ab63979. The last 385 nucleotide region of the HCV ant...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetGag-Pol polyprotein(HIV-1)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577438(US11472826, # 26)
Affinity DataIC50: 50nMAssay Description:Recombinant full length HIV-1 Reverse Transcriptase (HIVrt) was purchased from Abcam, catalog #ab63979. The last 385 nucleotide region of the HCV ant...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetGag-Pol polyprotein(HIV-1)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM577439(US11472826, # 27)
Affinity DataIC50: 50nMAssay Description:Recombinant full length HIV-1 Reverse Transcriptase (HIVrt) was purchased from Abcam, catalog #ab63979. The last 385 nucleotide region of the HCV ant...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 63 total ) | Next | Last >>
Jump to: